Benitec Biopharma Inc. · NASDAQ:BNTC
Benitec Biopharma — Benitec — Investor Presentation (February 2004)
19 slides from Benitec Biopharma's investor presentation, Feb 20, 2004
Slide 1: Benitec
Rx NAi ™ Benitec 2004 © copyright Benitec Australia Ltd 2002, 2003, 2004
Slide 2: Disclaimer
Disclaimer This presentation and any related documentation (hereinafter “presentation”) has been prepared and copyrighted by Benitec Limited and related entities (hereinafter “Benitec”) for general information purposes and while every care has been taken in relation to its accuracy and completeness,
Slide 3: The global leader in RNAi therapeutics
RxNAi ™ The global leader in RNAi therapeutics © copyright Benitec Australia Ltd 2002, 2003, 2004
Slide 4: Benitec's Strategy
Benitec’s Strategy z Benitec is using its unique patent position in ddRNAi to develop proprietary treatments for catastrophic diseases, both in-house and in collaboration z Benitec is providing research and commercial licenses to its global issued patents to support the funding of its clinical progr
Slide 5: Corporate Status
Corporate Status z Publicly listed on Australian Stock Exchange (ASX: BLT) z Traded on Deutsche Borse (Xetra), Frankfurt & Berlin Bremen Stock Exchanges z Top 10 ASX performing stocks for 2002/03 z Current market cap ca. US$70m z Issued shares: 73.6m; options: 17m (12m ex-Dec. 2004) z Operational fa
Slide 6: Management Team
Management Team John McKinley 15 years’ Biotech experience in European Executive Chairman & CEO public and private biotech companies as Director and CEO; formerly UK solicitor specializing in Company and IP law Prof Ken Reed 30 years’ Biotech experience; formerly Director, Research & Technology Dire
Slide 7: Technology – RNAi
Technology – RNAi ¾ A powerful new method for discovering and developing drugs based on targeted gene silencing ¾ Disease results from aberrant proteins, encoded by abnormal gene variants ¾ RNAi is a natural cellular mechanism that selectively negates gene expression • Improper protein synthesis is
Slide 8: Technology – DNA-directed RNAi
Technology – DNA-directed RNAi ¾ Specific destruction of messenger RNA (mRNA) by RNA interference (RNAi), triggered by DNA constructs ¾ Benitec pioneered DNA-directed RNAi (ddRNAi) and patented the technology in 1998 • DNA construct inserted into cell, which produces double stranded RNA (dsRNA) • si
Slide 9: Technology – RNAi Advantage
Technology – RNAi Advantage siRNAi ddRNAi Advantages to ddRNAi RNA-based DNA - based • INCREASED STABILITY – Ease of handling •COST SAVINGS – High throughout screening possible – expensive modifications unnecessary • Short dsRNA only • Variable length dsRNA • INCREASED APPLICABILITY – several genes
Slide 10: The ddRNAi Advantage
The ddRNAi Advantage • Delivery, Delivery, Delivery… • Stable • Targeted • Flexible • Controllable with proven efficient and effective vehicles • Powerful • Multi-hit • Multi-target • Optimised targets • Ultra-Fast, Ultra-Efficient • Low cost, in-house, high throughput preparation • HTP screening, w
Slide 11: ddRNAi Reduces Time to Clinic
ddRNAi Reduces Time to Clinic The current path to drug development... >US$800m approx. 8–10 years Target Target Candidate Clinical Gene Target Lead Lead Validation Validation Drug ADME/Tox Trials: Discovery Identification Identification Optimization in vitro in vivo Screening P1, P2, P3 ddRNAi provi
Slide 12: Benitec's Competitive Advantage
Benitec’s Competitive Advantage z Earliest patents for RNAi in humans and mammals z The only issued patents for RNAi in humans and mammals z 7 patents granted; >60 patents pending; 19 jurisdictions z Dedicated partner providing licensed ddRNAi materials z Unique Rx platform z Pioneer in RNAi knowhow
Slide 13: RNAi Discovery Timelines
RNAi Discovery Timelines Mammalian RNAi Mammalian RNAi by DNA delivery by ddRNAi TRANSCRIBABLE TRANSCRIBABLE (Glover) (Agami) DNA DNA CONSTRUCTS CONSTRUCTS Mammalian RNAi Mammalian RNAi by DNA delivery by ddRNAi in vivo (Pachuk) (Kay) Plant Mammalian US 6,573,099 RNAi co-suppression by DNA (Graham)
Slide 14: Benitec & Promega 2003/04
Benitec & Promega 2003/04 z Signed on April 8th, 2003 as first licensing deal for Benitec z Promega acquired worldwide exclusive license to develop, sell and distribute DNA-delivered RNAi (ddRNAi) products and to issue research licenses (FTO) for non-therapeutic use z Provides global offering of con
Slide 15: Milestones Achieved 2003
Milestones Achieved 2003 z Achieved leading technology and corporate profile z IP certainty and strategic alliance with CSIRO z Patent grants – US, UK, Australia and NZ (7 in total) z Investment: December 2003 equity raising of AUD$10.92 million issuing 9.1 million new shares z dd product developmen
Slide 16: Commercial Strategy 2004
Commercial Strategy 2004 BUSINESS MODEL • Establish long term shareholder value with high-value therapeutic development programs • Use strategic collaborations to reduce funding requirements • Use revenue streams from FTO licensing and discovery tools to underpin corporate and therapeutic developmen
Slide 17: Commercial Strategy 2004
Commercial Strategy 2004 z Establish early pre-clinical trials with high value targets DRUGS AND THERAPEUTICS z Identify programs for accelerated trials status z Widespread dd application to serious diseases including cancers enables commercial licensing of targets to drug companies z dd technology
Slide 18: Anticipated Milestones 2004
Anticipated Milestones 2004 z Incorporate US companies and establish corporate presence z Recruit key business executives and appoint key advisors z Establish therapeutic disease targets programs z File INDs for ddRNAi therapeutic targets z Broaden SAB expertise and clinical support z Review US mark
Slide 19: Summary
Summary z Leading RNAi therapeutic Company z Unchallenged IP in ddRNAi z Exclusive rights for applications in humans z Focused approach to therapeutics development z Leveraging collaborations to avoid costly infrastructure build z Licensing revenue underpins growth z Recognized dd superiority and di